Doc. No.
`Ex. 1013
`
`Ex. 1014
`
`Ex. 1015
`
`Ex. 1016
`
`Ex. 1018
`
`Ex. 1021
`
`Ex. 1022
`
`Ex. 1031
`
`Ex. 2011
`Ex. 2015
`
`
`
`
`
`
`
`
`Materials Considered by Frank M. Sacks
`In Support of the Motion to Amend
`
`Case: IPR2015-01836
`Patent No. 7,932,268
`
`
`
`Description
`“Bayer/PPD Implitapide Development Follows Zetia Model”, THE
`PINK SHEET, Vol. 66, No. 7, p. 17 (2004)
`Evan Stein, “Microsomal Triglyceride Transfer Protein (MTP)
`Inhibitor (implitapide) program”, Presentation Given at PPD’s
`Analyst Day (February 5, 2004)
`Chang, et al., “Microsomal triglyceride transfer protein (MTP)
`inhibitors: Discovery of clinically active inhibitors using high-
`throughput screening and parallel synthesis paradigms”, CURRENT
`OPINION IN DRUG DISCOVERY & DEV., Vol. 5, No. 4, pp. 562-570
`(2002)
`Charles E. Chandler et al., CP-346086: an MTP inhibitor that
`lowers plasma cholesterol and triglycerides in experimental animals
`and in humans, 44 J. OF LIPID RES. 1887 (2003)
`Wetterau, et. al, “An MTP Inhibitor That Normalizes Atherogenic
`Lipoprotien Levels in WHHL Rabbits,” SCIENCE, Vol. 282, pp. 751-
`754 (1998)
`THOMPSON PDR, PHYSICIANS’ DESK REFERENCE 506-09, 1101-06,
`1813-21, 2036-41, 2126-31, 2547-51, 2729-31, 2865-68 (57th ed.
`2003) (excerpting product information for Tricor®, Pravachol®,
`Advicor®, Niaspan®, Mevacor®, Zocor®, Lipitor®, Colestid®, and
`Lescol®)
`THOMPSON PDR, PHYSICIANS’ DESK REFERENCE 2118-23, 3085-89
`(58th ed. 2004) (excerpting product information for Zetia®)
`Shiomi & Ito, MTP inhibitor decreases plasma cholesterol levels in
`LDL receptor-deficient WHHL rabbits by lowering the VLDL
`secretion, European Journal of Pharmacology, Vol. 431, pp. 127-
`131 (2001)
`“MTP inhibitor research discontinued”, THE PINK SHEET (2000)
`JUXTAPID label (2012)
`
`1
`
`
`
`
`
`UPENN EX. 2073
`CFAD v. PENN
`IPR2015-01836
`
`

`
`
`
`Doc. No.
`Ex. 2018
`
`Ex. 2019
`
`Ex. 2020
`
`Ex. 2031
`
`Ex. 2043
`
`Ex. 2053
`
`Ex. 2072
`
`Ex. 2086
`
`Ex. 2087
`
`Ex. 2088
`
`Ex. 2089
`Ex. 2090
`
`Ex. 2091
`Ex. 2092
`Ex. 2093
`Ex. 2094
`Ex. 2095
`
`
`
`
`
`
`
`
`Description
`Michael Mayersohn, Designing a Dosage Regimen: Drug Therapy,
`CLIN. THER., Vol. 10, No. 10 (Oct. 1980)
`Peter Jones et al., Comparative Dose Efficacy Study of Atorvastatin
`Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in
`Patients With Hypercholesterolemia (The CURVES Study, AM. J.
`CARDIOL., Vol. 81 (Mar. 1, 1998)
`Jeffrey A. Robl et al., A Novel Series of Highly Potent
`Benzimidazole-Based Microsomal Triglyceride Transfer Protein
`Inhibitors, J. MED. CHEM., Vol. 44, No. 6 (Mar. 15, 2001)
`Dr. Frank Sacks Materials Considered
`Frank M. Sacks et al., Severe Hypertriglyceridemia With
`Pancreatitis: Thirteen Years’ Treatment With Lomitapide, JAMA
`INTERN. MED., Vol. 174, No. 3 (Mar. 2014)
`Marc A. Pfeffer et al., Safety and tolerability of pravastatin in long-
`term clinical trials. Prospective Pravastatin Pooling (PPP) Project,
`CIRC. (May 21, 2002)
`Christopher P. Cannon et al., Intensive versus Moderate Lipid
`Lowering with Statins after Acute Coronary Syndromes, N. ENG. J.
`MED., Vol. 350, No. 15 (Apr. 8, 2004)
` Visioli, F., “Microsomoal triglyceride transfer protein inhibitors,”
`Current Opinion in Cardiovascular, Pulmonary & Renal
`Investigational Drugs 2000 2(3):292-293
` Williams, S. et al., “Novel microsomal triglyceride transfer protein
`inhibitors,” Expert Opin. Ther. Patents (2003) 13(4): 479-488
` Funatsu, T. et al. “Atorvastatin Increases Hepatic Fatty Acid Beta-
`Oxidation in Sucrose-Fed Rats: Comparison with an MTP Inhibitor”
`European Journal of Pharmacology 455 (2002) 161- 167
` Barclay, L., “Hyperlipidemia”, NMT Briefs, 2003, 1-4
` Evans, M., et al., “Medical Lipid-Regulating Therapy: Current
`Evidence, Ongoing Trials and Future Developments,” Drugs 2004:
`64 (11): 1181-1196
` US5760246A Biller S. et al., 1998
` Intentionally left blank
` WO 98/03069, Gregg R. et al.
` US6057339A, Gregg R., 2000
` US6066653A, Gregg R. et al., 2000
`
`2
`
`
`
`
`
`UPENN EX. 2073
`CFAD v. PENN
`IPR2015-01836
`
`

`
`
`
`Doc. No.
`Ex. 2096
`Ex. 2097
`Ex. 2098
`Ex. 2099
`Ex. 2100
`Ex. 2101
`Ex. 2102
`Ex. 2103
`
`Ex. 2104
`
`Ex. 2105
`
`Ex. 2106
`
`Ex. 2107
`
`Ex. 2108
`
`Ex. 2109
`
`Ex. 2110
`
`Ex. 2111
`
`Ex. 2112
`Ex. 2113
`Ex. 2114
`Ex. 2115
`Ex. 2116
`
`
`
`
`
`
`
`
`Description
` WO1998031367, Gregg R. et al.
` US6620821B2, Robl J., 2003
` US6627636B2 –Robl, J. 2003
` US6812345B2 – Robl, J. et al. 2004
` US7358254B2 – Robl, J. et al., 2008
` US5990110A, Firestone R., 1999
` WO 2005/097131, Engelen, M. et al.
` van Dam, M.J., Dyslipidemia; diagnosis and treatment, Dissertation,
`UvA-DARE, 2001, 147-157
` U.S. National Institutes of Health, Implitapide in Patients With
`Hypertriglyceridemia on Maximal, Concurrent Triglyceride-
`Lowering Therapy, NIH Clinical Trials.gov, NT0008013, 2004, 1-3
` U.S. National Institutes of Health, Implitapide in Patients With
`Homozygous Familial Hypercholesterolemia on Maximal
`Concurrent Lipid-Lowering Therapy, NIH Clinical Trials.gov,
`NCT00079846, 2003, 1-3
` Baddour, L. et al., PPD to Hold Analyst Day on February 5, 2004
`(Jan. 15, 2004)
` Gruetzmann R., et al., “Impiltapide inhibits secretation of apoB-
`associated lipoproteins by inhibition of the MTP,” Eur. Heart J.
`2000, 21 (Suppl), Abst 3271, p. 600.
` Bischoff, H., et al., Bay 13-9952 (implitapide): pharmacodynamic
`effects of a new MTP inhibitor on plasma lipids and adipose tissue
`in animals, Eur. Heart J. 2000, 21 (Suppl), Abst P3501, p. 636
` Zaiss, S., et al., 194, Bay 13-9952 (Implitapide), an inhibitor of the
`MTP, inhibits atherosclerosis and prolongs lifetime in apo-E
`knockout mice, Eur. Hert J. 2000, 21 (Suppl), Abst 194, p. 16
` Bayes, M., et al., Gateways to Clinical Trials, Methods Find Exp
`Clin Pharmacol 2002, 24(1): 37-55
` Sorbera, L.A., et al., Implitapide, Drugs of the Future, 2000, 25(11):
`1138-1144
` US20060135460A1, Widder K. et al., 2006
` WO 2006/063128, Widder K. et al.
` US20060153913A1, Yamane S. et al., 2006
` WO 2006/046623, Yamane S. et al.
` US20060211762A1, Rongen, R. et al., 2006
`
`3
`
`
`
`
`
`UPENN EX. 2073
`CFAD v. PENN
`IPR2015-01836
`
`

`
`
`
`Doc. No.
`Ex. 2117
`Ex. 2118
`Ex. 2119
`Ex. 2120
`Ex. 2121
`Ex. 2122
`Ex. 2123
`
`Ex. 2124
`
`Ex. 2125
`
`Ex. 2126
`Ex. 2127
`
`Ex. 2128
`
`Ex. 2129
`
`Ex. 2130
`
`Ex. 2131
`Ex. 2132
`Ex. 2133
`Ex. 2134
`Ex. 2135
`Ex. 2136
`Ex. 2137
`Ex. 2138
`Ex. 2139
`Ex. 2140
`Ex. 2141
`Ex. 2142
`
`
`
`
`
`
`
`Description
` WO 2006/062748, Rongen, R. et al.
` US20070098778A1, Borsadia S., 2007
` WO 2005/084666, Borsadia S.
` WO 96/26205, Wetterau, J. et al.
` WO 98/03174, Firestone, R.
` WO 98/27979, Tino, J.
` Aguilar-Salinas, C., et al., Efficacy and safety of atorvastatin in
`hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter,
`open-label study, Eslevier, Atheroslerosis, 2000, 489-496
` Capuzzi, D., et al., Niacin Dosing: Relationship to Benefits and
`Adverse Effect, Current Atherosclerosis Reports, 2000, 2, 64-71
` Teramoto T. et al.; Effect of large dose of niceritrol (Perycit) on
`hypercholesterolemia –by administering Gradually Increasing
`Doses, Hardening of the arteries (1991), 199-208
` Reference 4 cited in JPA No. 2007-502093, Vol. 40, 3389-3397.
` Knopp R., Treatment of Lipid Disorders, New England Journal of
`Medicine, August, 1999,Vol. 341:498-511
` Bays, H. et al., Pharmacotherapy for dyslipidaemia - current
`therapies and future agents, Expert Opin. Pharmacother. (2003)
`4(11), 1901-38
` Bruckert, E., New lipid-modifying therapies, Expert Opin. lnvescig.
`Drugs (2003) 12(3): 325-335
` Kastelein, J., What future for combination therapies? Int. J. Clin.
`Pract. Suppl. Mar. 2003, (134), 45-50
` US4686237A, Anderson, P., 1987
` WO 98 31366, Behounek, E. et al.
` US6194454B1, Dow, R., 2001
` US20020035064A1, Robl, J. et al, 2002
` US20080248070A1, Tunac J, 2008
` US20050101561A, Tunac J., 2005
` WO 98/31225, Gregg, R.
` WO 98/50028, Gregg, R. et al.
` US6875782B2, Cheng, P. et al., 2005
` US20030109543A1, Ogletree, M., 2003
` US20040058908A1, Keller, B, et al., 2004
` WO 00/38725, Keller, B, et al.
`4
`
`
`
`
`
`UPENN EX. 2073
`CFAD v. PENN
`IPR2015-01836
`
`

`
`
`
`Doc. No.
`Ex. 2143
`Ex. 2144
`Ex. 2145
`Ex. 2146
`Ex. 2147
`
`Ex. 2148
`
`Ex. 2149
`
`Ex. 2150
`
`Ex. 2151
`
`Ex. 2152
`
`Ex. 2153
`
`Ex. 2154
`Ex. 2155
`Ex. 2156
`Ex. 2157
`Ex. 2158
`Ex. 2159
`Ex. 2160
`Ex. 2161
`Ex. 2162
`Ex. 2163
`Ex. 2164
`Ex. 2165
`
`
`
`
`
`
`
`
`Description
` US20070099884A1, Erondu, N, et al., 2007
` WO 2004/110375, Erondu, N, et al.
` WO 2005/000217, Erondu, N, et al.
` Microsomal Triglyceride Transfer Protein, 1-6
` Wetterau, J., et al., Microsomal triglyceride transfer protein,
`Biochimica et Biophysica Acta 1345 (1997) 136-150
` Thomas, L., Alleviation of MTP inhibitor-induced hepatic steatosis
`in hyperlipidemic fa/fa rats by fenofibrate, Department of Metabolic
`Diseases and Dept. of Chemical Research, Boehringer Ingelheim, 1
`page
` Wierzbicki, A., New lipid-lowering agents, Expert Opin. Emerging
`Drugs (2003) 8(2): 365-376
` Atzel, A., et al., Mechanism of Microsomal Triglyceride Transfer
`Protein Catalyzed Lipid Transport, Biochemistry 1993, 32, 10444-
`10450
` Bakillah, A., et al., Decreased Secretion of ApoB Follows Inhibition
`of ApoB-MTP Binding by a Novel Antagonist, Biochemistry 2000,
`39, 4892-4899
` Jamil, H., et al., An inhibitor of the microsomal triglyceride transfer
`protein inhibits apoB secretion from HepG2 cells, Proc. Natl. Acad.
`Sci. USA, Vol. 93, 1996. 11991-11995
` Liao, W., et al., Blocking microsomal triglyceride transfer protein
`interferes with apoB secretion without causing retention or stress in
`the ER, Journal of Lipid Research, Volume 44, 2003, 978-985
` US5789197A, Wetterau II, J. et al., 1998
` US6492365B1, Wetterau II, J. et al., 2002
` US6720351B2, Bertinato, P, et al., 2004
` US20030187053, Bertinato, P, et al.
` US6979692B2, Bertinato, P, et al., 2005
` US20020045271A1, Hussain M. et al., 2002
` US20040014748A1, Grutzmann R. et al., 2004
` US20060166999A1 - Grutzmann R. et al., 2006
` US20050090426A1, Blumberg R., 2005
` US20060205726A1, Hagiwara, A., 2006
` EP 1 181 954, Chang, G., et al.
` EP 1 099 442, Chang, G., et al.
`
`5
`
`
`
`
`
`UPENN EX. 2073
`CFAD v. PENN
`IPR2015-01836
`
`

`
`
`
`Doc. No.
`Ex. 2166
`Ex. 2167
`Ex. 2168
`Ex. 2169
`Ex. 2170
`Ex. 2171
`Ex. 2172
`Ex. 2173
`Ex. 2174
`
`Ex. 2175
`
`Ex. 2176
`
`Ex. 2177
`
`Ex. 2178
`
`Ex. 2179
`Ex. 2180
`
`Ex. 2181
`
`Ex. 2182
`
`Ex. 2183
`Ex. 2184
`
`
`
`
`
`
`
`
`Description
` DE19951022, Chang, G., et al.
` CA 2,091,102, Wetterau II, J. et al.
` CA 2291471, Chang, G., et al.
` WO 96/40640, Chang, G., et al.
` JP2002220345, Takeshi, N., et al.
` WO 97/41111, Urban, F.
` WO 2005/051382, Moritani, H., et al.
` WO 2005/094864, Eaton, S., et al.
` Parsons, C.G., et al., Memantine is a clinically well tolerated
`NMDA receptor antagonist - a review of preclinical data,
`Neuropharmacology 38 (1999) 735-767
` Catapano, A.L., Ezetimibe: a selective inhibitor of cholesterol
`absorption, European Heart Journal Supplements (2001) 3
`(Supplement E), E6-E10
` Capson, T., Synthesis and Evaluation of Ammonium Analogs of
`Carbocationic Intermediates in Squalene Biosynthesis, Dissertation,
`Department of Med. Chem., The University of Utah, Vol. 4803B of
`Dissertations Abstracts International, 1987, Abstract
` Corey, E.J., et al. Application of Unreactive Analogs of Terpenoid
`Pyrophsphates to Studies of Multistep Biosynthesis, Demonstration
`That “Presqualene Pyrophosphate” is an Essential Intermediate on
`the Path to Squalene, Journal. Of the American Chemical Society,
`98:5, 1976, 1291-93
` De Montellano, P., et al., Inhibition of Squalene Synthetase by
`Farnesyl Pyrophosphate Analogues, Journal of Medicinal
`Chemistry, 1977, Vol. 20, 243-49
` Earl, J., et al., Ezetimbe, Nature Reviews, Vol. 2, 2003, 97
` National Cholesterol Education Program, Adult Treatment Panel III
`Report, 2001, 373 pages
` Farrell, G., Drugs and Steatohepatitis, Seminars in Liver Disease,
`Vol. 22, No. 2, 2002, 185-194
` Gagne, C., et al., Efficacy and Safety of Ezetimibe Coadministered
`With Atorvastatin or Simvastatin in Patients with Homozygous
`Familial Hypercholesterolemia, Circulation, 2002; 105:2469-2475
` Kirkpatrick, P., et al., Market Indicators, Nature, Vol. 2, 2003, 98
` McClard, R., Novel Phosphonylphosphinyl Analogues of
`
`6
`
`
`
`
`
`UPENN EX. 2073
`CFAD v. PENN
`IPR2015-01836
`
`

`
`
`
`Doc. No.
`
`Ex. 2185
`
`Ex. 2186
`
`Ex. 2187
`Ex. 2188
`Ex. 2189
`Ex. 2190
`Ex. 2191
`Ex. 2192
`Ex. 2193
`Ex. 2194
`Ex. 2195
`Ex. 2196
`Ex. 2197
`Ex. 2198
`Ex. 2199
`Ex. 2200
`Ex. 2201
`Ex. 2202
`Ex. 2203
`Ex. 2204
`Ex. 2205
`Ex. 2206
`Ex. 2207
`Ex. 2208
`Ex. 2209
`Ex. 2210
`Ex. 2211
`Ex. 2212
`Ex. 2213
`
`
`
`
`
`
`
`Description
`Biochemically Interesting Diphosphates, Syntheses and Properties
`of P-C-P-C Analogues of Isopentenyl Diphosphate and
`Dimethylally Diphosphate, J. Am. Chem. Soc., 1987, 109, 5544-5
` Ritter, T., et al., Heterocyclic ring scaffolds as small-molecule
`cholesterol absorption inhibitors, Org. Biomol. Chem., 2005, 3,
`3514-3523
` Sudhop, T., et al., Cholesterol Absorption Inhibitors for the
`Treatment of Hypercholesterolaaemia, Drugs, 2002; 62(16), 2333-
`2347
` US3983140A, Endo, A. et al., 1976
` US4231938A, Monaghan, R., et al., 1980
` US4346227A, Terahara, A., 1982
` US4448784A, Glamkowski E., et al., 1984
` US4450171A, Hoffman, W., et al., 1984
` US4499289A, Baran, J., 1985
` US4613610A, Waring, J., 1986
` US4647576A, Hoefle, M., et al., 1987
` US4716175B1, Hoefle, M., et al., 1987
` US4871721A, Biller, S., 1989
` US4924024A, Biller, S., 1990
` US5015644A, Roth, B. et al., 1991
` US5026554A, Bartizal, K., et al., 1991
` US5117080A, Lee, K., 1992
` US5510379A, Lee, H., et al., 1996
` US5595872A, Wetterau II, J., et al., 1997
` US5684014A, Muller, U. et al., 1997
` EP0705831, Muller, U. et al.
` US5712396A, Magnin D., et al., 1998
` US5767115A, Rosenblum, S., et al., 1998
` US5786361A, Muller, U., et al., 1998
` EP 0 802 198, Muller, U., et al.
` US5811429A, Connell, R., et al., 1998
` EP0779279, Connell, R., et al.
` US5827875A, Dickson, J., 1998
` US5885983A, Biller S., et al., 1999
` US5952498A, Lenfers, J., et al., 1999
`7
`
`
`
`
`
`UPENN EX. 2073
`CFAD v. PENN
`IPR2015-01836
`
`

`
`
`
`Doc. No.
`Ex. 2214
`Ex. 2215
`Ex. 2216
`Ex. 2217
`Ex. 2218
`Ex. 2219
`Ex. 2220
`Ex. 2221
`Ex. 2222
`Ex. 2223
`Ex. 2224
`Ex. 2225
`Ex. 2226
`Ex. 2227
`Ex. 2228
`Ex. 2229
`Ex. 2230
`Ex. 2231
`Ex. 2232
`Ex. 2233
`Ex. 2234
`Ex. 2235
`Ex. 2236
`Ex. 2237
`Ex. 2238
`Ex. 2239
`Ex. 2240
`Ex. 2241
`Ex. 2242
`Ex. 2243
`Ex. 2244
`Ex. 2245
`Ex. 2246
`Ex. 2247
`Ex. 2248
`Ex. 2249
`
`
`
`
`
`
`
`Description
` US6034115A, Connell, R., et al., 2000
` EP 0 779 276, Connell, R., et al.
` US6066650A, Biller, S., et al., 2000
` US6114341A, Muller, U., et al., 2000
` EP0799828, Muller, U., et al.
` US6121283A, Chang, G., et al., 2000
` WO 98/23593, Chang, G., et al.
` US6140343A, DeNinno, M., et al., 2000
` US6245775B1, Muller, U., et al., 2001
` US6265431B1, Muller, U., et al., 2001
` US6297233B1, Stein, P., et al., 2001
` US6344450B1, Bisacchi, G., et al., 2002
` US6479503B2, Muller, U., et al., 2002
` US6858622B2, Muller, U., et al., 2005
` US6498156B2, Glombik, H., et al., 2002
` US6774236B1, Lenfers, J., 2004
` US6846836B2, Hamann, L., et al., 2005
` US6884812B2, Glombik, H., et al., 2005
` US6916809B2, Chen, P., et al., 2005
` US6916813B2, Atwal, K., et al., 2005
` US7053080B2, Davis, H., et al., 2006
` US7056906B2, Strony J., 2006
` US7394501B2, Iwata, T., 2008
` US20030069221A1, Kosoglou, T., et al., 2003
` US20030153541A1, Dudley, R., et al., 2003
` US20030162788A1, Thomas, L., et al., 2003
` US20050075367A1, Hagiwara, A., et al., 2005
` US20060069161A1, Lee, M., et al., 2006
` US20060160834A1, Fong, T., et al., 2006
` WO 2004/110368, Fong, T., et al.
` US20060211020A1, Farrer, L., et al., 2006
` US20070027093A1, Ogawa, N., et al., 2007
` WO 2005/072740, Ogawa, N., et al.
` US20070032404A1, Sweet, L., 2007
` US20080016127A1, Field, S., 2007
` EP0142146, Hoffman W., et al.
`8
`
`
`
`
`
`UPENN EX. 2073
`CFAD v. PENN
`IPR2015-01836
`
`

`
`
`
`Doc. No.
`Ex. 2250
`Ex. 2251
`Ex. 2252
`Ex. 2253
`Ex. 2254
`Ex. 2255
`Ex. 2256
`Ex. 2257
`Ex. 2258
`Ex. 2259
`Ex. 2260
`Ex. 2261
`
`Ex. 2262
`
`Ex. 2263
`
`Ex. 2264
`
`Ex. 2265
`
`Ex. 2266
`Ex. 2267
`Ex. 2268
`Ex. 2269
`Ex. 2270
`Ex. 2271
`Ex. 2272
`Ex. 2273
`Ex. 2274
`
`
`
`
`
`
`
`Description
` GB 2205837, Karanewsky, D., et al.
` FR2596393, Jean, C., et al.,
` WO 0108679, Verkade, H.
` WO 2004/028544, Grondahl, C., et al.
` WO 86/03488, Kathawala, F., et al.
` WO 86/07054, Wareing, J.
` EP0221025, Wareing, J., et al.,
` EP0325130, Rolf, A., et al.
` WO 96/26948, Fancelli, D., et al.
` WO 2005/033100, Carreira, E., et al.
` JP 2003-321424, Hagiwara, A., et al.
` Hussain, M., et al., Multiple functions of microsomal triglyceride
`transfer protein, Nutrition & Metabolism, 2012, 9:14, 1-16
` Li. J., et al., Bioorganic & Medicinal Chemistry Letters 16 (2006)
`3039-3042
` Looije, N., et al., Disodium Ascorbyl Phytostanyl Phosphates
`reduces plasma cholesterol concentration, body weight and
`abdominal fat gain within a dietary-induced obese mouse model, J
`Pharm Pharmaceut Sci 8 (3):400-408, 2005
` Aggarwal, D., et al., JTT-130, a microsomal triglyceride transfer
`protein inhibitor lowers plasma triglycerides and LDL cholesterol
`concentrations without increasing hepatic triglycerides in guinea
`pigs, BMC Cardiovascular Disorders 2005, 5:30, 1-8
` Samaha, F., et al., Inhibition of microsomal triglyceride transfer
`protein alone or with ezetimibe in patients with moderate
`hypercholesterolemia, Nature Clinical Practice, Cardiovascular
`Medicine, August 2008, Vol. 5 No. 8, 497-505
` US7645732B2, Ye, J., et al., 2010
` US20060252733A1, Jansen, B., 2006
` US20060270655A1, Swick, A., et al., 2006
` US20070088089A1, Wisler, G., 2007
` US20070093468A1, Wisler, G., 2007
` US20070093527A1, Wisler, G., 2007
` US20080033019A1, Stamler, J., 2008
` US20080051427A1, Shuckler, F., 2008
` US20080103122A1, Veltri, E., 2008
`9
`
`
`
`
`
`UPENN EX. 2073
`CFAD v. PENN
`IPR2015-01836
`
`

`
`
`
`Doc. No.
`Ex. 2275
`Ex. 2276
`Ex. 2277
`Ex. 2278
`Ex. 2279
`Ex. 2280
`Ex. 2281
`Ex. 2282
`Ex. 2283
`Ex. 2284
`Ex. 2285
`Ex. 2286
`Ex. 2287
`Ex. 2288
`Ex. 2289
`Ex. 2290
`Ex. 2291
`Ex. 2292
`Ex. 2293
`Ex. 2294
`Ex. 2295
`Ex. 2296
`Ex. 2297
`Ex. 2298
`Ex. 2299
`
`
`
`
`
`
`
`
`Description
` US20080161279A1, Wisler, G., 2008
` US20080175864A1, Ye J., et al., 2008
` US20080241869A1, Davis, R., 2008
` US20080253985A1, Wisler, G., 2008
` US20080255084A1, Webb, R., 2008
` US20080280992A1, Kunz, K., et al., 2008
` US20090042835A1, Davis, R., 2009
` US20090054393A1, Wisler, G., 2009
` US20090093527A1, Li, C., et al., 2009
` US20100273829A1, Wisler, G., 2010
` WO 2006/108666, Schrattenholz, A.
` WO 2006/111238, Chevreuil, O., et al.
` WO 2007/047880, Wisler, G.
` WO 2007/047724, Wisler, G.
` WO 2008/012056, Pacholik, J., et al.
` WO 2008/021353, Luo, G.
` WO 2008/030382, Veltri, E.
` WO 2008/072061, Gossellin, J., et al.
` WO 2008/075949, Troost, F., et al.
` WO 2008/079398, Wisler, G.
` WO 2008/090198, King, P., et al.
` WO 2008/115574, Bobotas, G., et al.
` US 7932268 Rader et al.
` US 6949572 Bertinato et al.
` US 20090042941 Rader et al.
`
`
`10
`
`
`
`
`
`UPENN EX. 2073
`CFAD v. PENN
`IPR2015-01836